WHEN SKIN TURNS AGAINST THE BODY: A CLOSER LOOK AT SJS AND TEN

Karolina Ochyra; Martyna Bukała; Kornelia Pudło; Jowita Frydrych; Gabriela Godek; Karolina Ryba; Katarzyna Znamirowska; Klaudia Zacher; Anna Rakoczy; Patrycja Walkiewicz

doi:10.31435/ijitss.4(48).2025.4151

Authors

Karolina Ochyra Medical Center in Łańcut, Łańcut, Poland https://orcid.org/0009-0009-7525-3014
Martyna Bukała Medical Center in Łańcut, Łańcut, Poland https://orcid.org/0009-0002-9288-4140
Kornelia Pudło Independent Public Health Care Complex No. 1 in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0007-1415-6048
Jowita Frydrych University Teaching Hospital them. F. Chopin in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0003-5416-7252
Gabriela Godek University Teaching Hospital them. F. Chopin in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0003-6633-6498
Karolina Ryba University Teaching Hospital them. F. Chopin in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0007-4305-8375
Katarzyna Znamirowska University Teaching Hospital them. F. Chopin in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0005-6760-2174
Klaudia Zacher Medical Center in Łańcut, Łańcut, Poland https://orcid.org/0009-0003-8839-9668
Anna Rakoczy University Teaching Hospital them. F. Chopin in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0001-1096-161X
Patrycja Walkiewicz University Teaching Hospital them. F. Chopin in Rzeszów, Rzeszów, Poland https://orcid.org/0009-0002-0492-9485

DOI:

https://doi.org/10.31435/ijitss.4(48).2025.4151

Keywords:

Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), Severe Cutaneous Adverse Reactions (SCARs), Clinical Presentation, Diagnostic Criteria, Prognostic Scoring Systems (SCORTEN, ABCD-10, CRISTEN), Therapeutic Strategies

Abstract

Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis are very rare, severe, life-threatening dermatological conditions characterized by severe skin and mucosal changes. The most common triggers are drugs, including β-lactam antibiotics, allopurinol, nonsteroidal anti-inflammatory drugs, nevirapine, and febuxostat. This article reviews the literature from 2000-2025 on the clinical manifestations that characterize SJS/TEN, pathogenesis, diagnosis necessary for proper treatment, prognostic scales such as SCORTEN, ABCD-10 and CRISTEN useful for predicting patient mortality, and treatment. Due to the rarity and high mortality rate of people with SJS/TEN, there is still a lack of high-quality studies on the pathogenesis of the disease and evaluating the efficacy of immunomodulatory drugs in inhibiting epidermal necrolysis and reducing mortality.

References

Koffi NR, Pete Y, N'Da KC, Ory OA, One JL, Ogondon B, Kouadio S, Able E, Irie B, Kouame KE, Brouh Y. Ibuprofen Lyell's Syndrome In An Eight-Year-Old Child. Ann Burns Fire Disasters. 2023 Mar 31;36(1):68-73. PMID: 38680905; PMCID: PMC11044737.

Hama N, Aoki S, Chen CB, Hasegawa A, Ogawa Y, Vocanson M, Asada H, Chu CY, Lan CE, Dodiuk-Gad RP, Fujiyama T, Hsieh TS, Ito K, Jerschow E, Mizukawa Y, Nakajima S, Nakamura K, Nicolas JF, Satoh TK, Shiohara T, Takahashi H, Tohyama M, Ueda T, Ura K, Watanabe H, Yamaguchi Y, Nordmann TM, Chung WH, Naisbitt D, Pincelli C, Pichler WJ, French LE, Phillips E, Abe R. Recent progress in Stevens-Johnson syndrome/toxic epidermal necrolysis: diagnostic criteria, pathogenesis and treatment. Br J Dermatol. 2024 Dec 23;192(1):9-18. doi: 10.1093/bjd/ljae321. PMID: 39141587.

Chang WC, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, Bellón T, Biala AK, Bouchard C, Cavalleri GL, Chapman N, Chodosh J, Choi HK, Cibotti RR, Divito SJ, Dewar K, Dehaeck U, Etminan M, Forbes D, Fuchs E, Goldman JL, Holmes JH 4th, Hope EA, Hung SI, Hsieh CL, Iovieno A, Jagdeo J, Kim MK, Koelle DM, Lacouture ME, Le Pallec S, Lehloenya RJ, Lim R, Lowe A, McCawley J, McCawley J, Micheletti RG, Mockenhaupt M, Niemeyer K, Norcross MA, Oboh D, Olteanu C, Pasieka HB, Peter J, Pirmohamed M, Rieder M, Saeed HN, Shear NH, Shieh C, Straus S, Sukasem C, Sung C, Trubiano JA, Tsou SY, Ueta M, Volpi S, Wan C, Wang H, Wang ZQ, Weintraub J, Whale C, Wheatley LM, Whyte-Croasdaile S, Williams KB, Wright G, Yeung SN, Zhou L, Chung WH, Phillips EJ, Carleton BC. SJS/TEN 2019: From science to translation. J Dermatol Sci. 2020 Apr;98(1):2-12. doi: 10.1016/j.jdermsci.2020.02.003. Epub 2020 Mar 7. Erratum in: J Dermatol Sci. 2021 Nov;104(2):146-147. doi: 10.1016/j.jdermsci.2021.09.008. PMID: 32192826; PMCID: PMC7261636.

Micheletti RG, Chiesa-Fuxench Z, Noe MH, Stephen S, Aleshin M, Agarwal A, Boggs J, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Gordon S, Hamrick R, Ho B, Hughey LC, Jones LM, Kaffenberger BH, Kindley K, Kroshinsky D, Kwong BY, Miller DD, Mostaghimi A, Musiek A, Ortega-Loayza AG, Patel R, Posligua A, Rani M, Saluja S, Sharon VR, Shinkai K, John JS, Strickland N, Summers EM, Sun N, Wanat KA, Wetter DA, Worswick S, Yang C, Margolis DJ, Gelfand JM, Rosenbach M. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. J Invest Dermatol. 2018 Nov;138(11):2315-2321. doi: 10.1016/j.jid.2018.04.027. Epub 2018 Jul 27. Erratum in: J Invest Dermatol. 2019 Feb;139(2):495-496. doi: 10.1016/j.jid.2018.11.013. PMID: 29758282.

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ. SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. J Allergy Clin Immunol Pract. 2018 Jan-Feb;6(1):38-69. doi: 10.1016/j.jaip.2017.11.023. PMID: 29310768; PMCID: PMC5857362.

Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orphanet J Rare Dis. 2010 Dec 16;5:39. doi: 10.1186/1750-1172-5-39. PMID: 21162721; PMCID: PMC3018455.

Sooranahalli C, Rao VR, Zelman B, Shekhar M, Komurlu Keceli S, Bouchard C, Iqbal O. The Potential Roles of IL-1β, IL-6, and RIPK3 in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. Diagnostics (Basel). 2025 Jan 26;15(3):290. doi: 10.3390/diagnostics15030290. PMID: 39941220; PMCID: PMC11816709.

Clark AE, Fook-Chong S, Choo K, Oh CC, Yeo YW, Pang SM, Lee HY. Delayed admission to a specialist referral center for Stevens-Johnson syndrome and toxic epidermal necrolysis is associated with increased mortality: A retrospective cohort study. JAAD Int. 2021 May 6;4:10-12. doi: 10.1016/j.jdin.2021.03.008. PMID: 34409382; PMCID: PMC8361915.

Ingen-Housz-Oro S, Matei I, Gaillet A, Gueudry J, Zaghbib K, Assier H, Hua C, Bensaid B, Colin A, Ouedraogo R, Redlich J, Courtois E, Chazelas K, Sbidian E, Nakad L, Bequignon E, Terkmane N, Gaultier F, Schlemmer F, Do-Pham G, Barbaud A, Lebrun-Vignes B, Hoffmann C, Mahé PJ, Le Floch R, Bernier C, Vabres B, Milpied B, Delcampe A, Tétart F, Tauber M, Staumont-Sallé D, Dezoteux F, Descamps V, Misery L, Bursztejn AC, Dereure O, Amazan E, Le Bidre E, Le Pallec S, Lagier C, Laroche A, Ferrat E, Wolkenstein P, de Prost N; French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions TOXIBUL. French national protocol for diagnosis and management of epidermal necrolysis in adults (Stevens-Johnson syndrome and toxic epidermal necrolysis). Ann Dermatol Venereol. 2024 Jun;151(2):103282. doi: 10.1016/j.annder.2024.103282. Epub 2024 May 28. PMID: 38810539.

Breidung D, Delavari S, Megas IF, Geierlehner A, Hitzl W, Bodenschatz KJ, Karcz K, Ehrl D, Billner M. Epidemiological Characteristics and Prognostic Scoring in Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: Insights from a 17-Year Burn Center Experience. Medicina (Kaunas). 2025 Jan 3;61(1):66. doi: 10.3390/medicina61010066. PMID: 39859048; PMCID: PMC11767146.

Yamane Y, Matsukura S, Watanabe Y, Yamaguchi Y, Nakamura K, Kambara T, Ikezawa Z, Aihara M. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. Allergol Int. 2016 Jan;65(1):74-81. doi: 10.1016/j.alit.2015.09.001. Epub 2015 Oct 9. PMID: 26666483.

Swarup A, Ta CN, Wu AY. Molecular mechanisms and treatments for ocular symblephara. Surv Ophthalmol. 2022 Jan-Feb;67(1):19-30. doi: 10.1016/j.survophthal.2021.04.008. Epub 2021 Apr 29. PMID: 33932469; PMCID: PMC8553799.

Wibowo E, Maharani RV, Sutikno NA. Symblepharon as Ocular Manifestation Post Stevens-Johnson Syndrome: A Rare Case. Rom J Ophthalmol. 2024 Oct-Dec;68(4):466-469. doi: 10.22336/rjo.2024.84. PMID: 39936062; PMCID: PMC11809831.

Shah H, Parisi R, Mukherjee E, Phillips EJ, Dodiuk-Gad RP. Update on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Diagnosis and Management. Am J Clin Dermatol. 2024 Nov;25(6):891-908. doi: 10.1007/s40257-024-00889-6. Epub 2024 Sep 15. PMID: 39278968; PMCID: PMC11511757.

Cheng L. Current Pharmacogenetic Perspective on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Front Pharmacol. 2021 Apr 26;12:588063. doi: 10.3389/fphar.2021.588063. PMID: 33981213; PMCID: PMC8107822.

Lin M, Gong T, Ruan S, Lv X, Chen R, Su X, Cheng B, Ji C. Emerging Insights into Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Induced by Immune Checkpoint Inhibitor and Tumor-Targeted Therapy. J Inflamm Res. 2024 Apr 17;17:2337-2351. doi: 10.2147/JIR.S454673. PMID: 38645875; PMCID: PMC11032673.

Su SC, Mockenhaupt M, Wolkenstein P, Dunant A, Le Gouvello S, Chen CB, Chosidow O, Valeyrie-Allanore L, Bellon T, Sekula P, Wang CW, Schumacher M, Kardaun SH, Hung SI, Roujeau JC, Chung WH. Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. J Invest Dermatol. 2017 May;137(5):1065-1073. doi: 10.1016/j.jid.2016.11.034. Epub 2016 Dec 21. PMID: 28011147.

Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, Chin SW, Chiou CC, Chu SC, Ho HC, Yang CH, Lu CF, Wu JY, Liao YD, Chen YT. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008 Dec;14(12):1343-50. doi: 10.1038/nm.1884. Epub 2008 Nov 23. PMID: 19029983.

Bordeanu-Diaconescu EM, Grama S, Grosu-Bularda A, Frunză A, Dumitru CŞ, Andrei MC, Creangă CA, Neagu TP, Lascăr I. Toxic epidermal necrolysis - clinicopathological aspects and therapeutic management. Rom J Morphol Embryol. 2024 Oct-Dec;65(4):765-773. doi: 10.47162/RJME.65.4.23. PMID: 39957038.

Abe R, Shimizu T, Shibaki A, Nakamura H, Watanabe H, Shimizu H. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003 May;162(5):1515-20. doi: 10.1016/S0002-9440(10)64284-8. PMID: 12707034; PMCID: PMC1851208.

Thakur V, Vinay K, Kumar S, Choudhary R, Kumar A, Parsad D, Kumaran MS. Factors Predicting the Outcome of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A 5-Year Retrospective Study. Indian Dermatol Online J. 2021 Mar 2;12(2):258-265. doi: 10.4103/idoj.IDOJ_437_20. PMID: 33959522; PMCID: PMC8088174.

Kumar P, Chauhan A, Charaniya R, Ghosh A, Tandon V. Metolazone Associated Stevens Johnson Syndrome-Toxic Epidermal Necrolysis Overlap. J Clin Diagn Res. 2016 Mar;10(3):FD01-2. doi: 10.7860/JCDR/2016/17768.7404. Epub 2016 Mar 1. PMID: 27134890; PMCID: PMC4843276.

Varol F, Can YY, Sahin E, Durak C, Kilic A, Sahin C, Gursoy F, Akin T. The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID-19. J Clin Apher. 2022 Oct;37(5):516-521. doi: 10.1002/jca.21997. Epub 2022 Jul 6. PMID: 35792366; PMCID: PMC9350357.

Jayte M, Jama YM, Athanus L. Nevirapine-Induced Stevens-Johnson Syndrome in an HIV-Infected Patient: A Case Report From Uganda. Int Med Case Rep J. 2025 Feb 13;18:249-253. doi: 10.2147/IMCRJ.S508884. PMID: 39963116; PMCID: PMC11831915.

Marazzi MC, Germano P, Liotta G, Guidotti G, Loureiro S, da Cruz Gomes A, Valls Blazquez MC, Narciso P, Perno CF, Mancinelli S, Palombi L. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med. 2006 Jul;7(5):338-44. doi: 10.1111/j.1468-1293.2006.00386.x. PMID: 16945080.

Chasela CS, Hudgens MG, Jamieson DJ, Kayira D, Hosseinipour MC, Kourtis AP, Martinson F, Tegha G, Knight RJ, Ahmed YI, Kamwendo DD, Hoffman IF, Ellington SR, Kacheche Z, Soko A, Wiener JB, Fiscus SA, Kazembe P, Mofolo IA, Chigwenembe M, Sichali DS, van der Horst CM; BAN Study Group. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010 Jun 17;362(24):2271-81. doi: 10.1056/NEJMoa0911486. PMID: 20554982; PMCID: PMC3440865.

Sidhu JK, Chopra D. Febuxostat induced Stevens Johnson syndrome: A case report. Int J Risk Saf Med. 2024 Nov;35(4):334-336. doi: 10.1177/09246479241292014. Epub 2024 Nov 5. PMID: 39973416.

Tana T, Vadas P. Febuxostat Desensitization in a Patient with Previous Stevens-Johnson Syndrome and HLA-B*58:01 Genotype. J Rheumatol. 2019 Sep;46(9):1250-1251. doi: 10.3899/jrheum.181051. Epub 2019 Jul 15. PMID: 31308200.

Ingen-Housz-Oro S, Matei I, Gaillet A, Gueudry J, Zaghbib K, Assier H, Wolkenstein P, de Prost N; French National Reference Center for Toxic Bullous Diseases and Severe Drug Reactions (TOXIBUL). Diagnosing and Managing Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Adults: Review of Evidence 2017-2023. J Invest Dermatol. 2025 Feb 27:S0022-202X(25)00078-8. doi: 10.1016/j.jid.2024.06.1295. Epub ahead of print. PMID: 40019457.

Ingen-Housz-Oro S, French LE, Wolkenstein P. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: How to Improve the Evaluation of Therapeutic Strategies. J Invest Dermatol. 2025 Feb 27:S0022-202X(25)00079-X. doi: 10.1016/j.jid.2024.08.043. Epub ahead of print. PMID: 40019455.

Hasegawa A, Abe R. Stevens-Johnson syndrome and toxic epidermal necrolysis: Updates in pathophysiology and management. Chin Med J (Engl). 2024 Oct 5;137(19):2294-2307. doi: 10.1097/CM9.0000000000003250. Epub 2024 Sep 5. PMID: 39238098; PMCID: PMC11441865.

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000 Aug;115(2):149-53. doi: 10.1046/j.1523-1747.2000.00061.x. PMID: 10951229.

Noe MH, Rosenbach M, Hubbard RA, Mostaghimi A, Cardones AR, Chen JK, Cotliar J, Davis MDP, Dominguez A, Fox LP, Hughey LC, Kaffenberger BH, Kroshinsky D, Kwong BY, Miller DD, Musiek A, Ortega-Loayza AG, Sharon VR, Shinkai K, Summers EM, Wanat KA, Wetter DA, Worswick S, Margolis DJ, Gelfand JM, Micheletti RG. Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. JAMA Dermatol. 2019 Apr 1;155(4):448-454. doi: 10.1001/jamadermatol.2018.5605. Erratum in: JAMA Dermatol. 2019 Sep 1;155(9):1090. doi: 10.1001/jamadermatol.2019.2200. Erratum in: JAMA Dermatol. 2019 Sep 1;155(9):1090. doi: 10.1001/jamadermatol.2019.2835.. Kroshinsky, Daniel [corrected to Kroshinsky, Daniela]. PMID: 30840032; PMCID: PMC6459085.

AlFada M, Alotaibi H, Alsharif S, Alani AH, Andrade-Miranda A, Montesinos Guevara C, Chen Y, Lei R, Acosta-Reyes J, Velásquez-Salazar P, El-Malky A, Amer YS. Systematic review, methodological appraisal, and recommendation mapping of clinical practice guidelines for managing patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. J Dermatolog Treat. 2025 Dec;36(1):2467751. doi: 10.1080/09546634.2025.2467751. Epub 2025 Feb 26. PMID: 40010698.

Tripathi A, Ditto AM, Grammer LC, Greenberger PA, McGrath KG, Zeiss CR, Patterson R. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc. 2000 Mar-Apr;21(2):101-5. doi: 10.2500/108854100778250914. PMID: 10791111.

Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. Acta Derm Venereol. 2007;87(2):144-8. doi: 10.2340/00015555-0214. PMID: 17340021.

Senda A, Fushimi K, Morishita K. Effect of Early Cyclosporine Treatment on Survival in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Cureus. 2024 Apr 8;16(4):e57862. doi: 10.7759/cureus.57862. PMID: 38721183; PMCID: PMC11078584.

Poizeau F, Gaudin O, Le Cleach L, Duong TA, Hua C, Hotz C, Ingen-Housz-Oro S, Sbidian E, Zehou O, Colin A, de Prost N, Lebrun-Vignes B, Chosidow O, Wolkenstein P, Fardet L. Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses. J Invest Dermatol. 2018 Jun;138(6):1293-1300. doi: 10.1016/j.jid.2017.12.034. Epub 2018 Jan 31. PMID: 29369774.

Ng QX, De Deyn MLZQ, Venkatanarayanan N, Ho CYX, Yeo WS. A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis. J Inflamm Res. 2018 Mar 28;11:135-142. doi: 10.2147/JIR.S160964. PMID: 29636627; PMCID: PMC5880515.

Wang CW, Yang LY, Chen CB, Ho HC, Hung SI, Yang CH, Chang CJ, Su SC, Hui RC, Chin SW, Huang LF, Lin YY, Chang WY, Fan WL, Yang CY, Ho JC, Chang YC, Lu CW, Chung WH; the Taiwan Severe Cutaneous Adverse Reaction (TSCAR) Consortium. Randomized, controlled trial of TNF-α antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018 Mar 1;128(3):985-996. doi: 10.1172/JCI93349. Epub 2018 Feb 5. PMID: 29400697; PMCID: PMC5824923.

Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol. 2003 Jan;139(1):33-6. doi: 10.1001/archderm.139.1.33. PMID: 12533161.

Tsai TY, Huang IH, Chao YC, Li H, Hsieh TS, Wang HH, Huang YT, Chen CY, Cheng YC, Kuo PH, Huang YC, Tu YK. Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. J Am Acad Dermatol. 2021 Feb;84(2):390-397. doi: 10.1016/j.jaad.2020.08.122. Epub 2020 Sep 6. PMID: 32898587.

Prins C, Kerdel FA, Padilla RS, Hunziker T, Chimenti S, Viard I, Mauri DN, Flynn K, Trent J, Margolis DJ, Saurat JH, French LE; TEN-IVIG Study Group. Toxic epidermal necrolysis-intravenous immunoglobulin. Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol. 2003 Jan;139(1):26-32. doi: 10.1001/archderm.139.1.26. PMID: 12533160.

Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenhaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol. 2008 Jan;58(1):33-40. doi: 10.1016/j.jaad.2007.08.039. Epub 2007 Oct 4. PMID: 17919775.

Miyamoto Y, Ohbe H, Kumazawa R, et al. Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatol. 2023;159(5):481–487. doi:10.1001/jamadermatol.2023.0035

Coromilas AJ, Divito SJ, Phillips EJ, Micheletti RG. Physical and mental health impact of Stevens-Johnson syndrome/toxic epidermal necrolysis and post-hospital discharge care: Identifying practice gaps. JAAD Int. 2023 Jan 30;11:88-89. doi: 10.1016/j.jdin.2023.01.012. PMID: 36941915; PMCID: PMC10023849.